Blueprint Medicines Co. (NASDAQ:BPMC) CEO Kate Haviland Sells 1,446 Shares

Blueprint Medicines Co. (NASDAQ:BPMC) CEO Kate Haviland sold 1,446 shares of Blueprint Medicines stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the transaction, the chief executive officer now directly owns 149,378 shares of the company’s stock, valued at $16,467,430.72. The trade was a 0.96 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kate Haviland also recently made the following trade(s):

• On Friday, November 29th, Kate Haviland sold 2,353 shares of Blueprint Medicines stock. The shares were sold at an average price of $96.60, for a total transaction of $227,299.80.

Blueprint Medicines Trading Up 4.1 %

NASDAQ BPMC opened at $115.63 on Friday. The company’s 50-day simple moving average is $95.28 and its two-hundred day simple moving average is $95.48. Blueprint Medicines Co. has a one year low of $72.24 and a one year high of $121.90. The company has a market capitalization of $7.35 billion, a price-to-earnings ratio of -54.80 and a beta of 0.61. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.08. The company had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. Blueprint Medicines’s revenue was up 126.5% compared to the same quarter last year. During the same period last year, the company posted ($2.20) earnings per share. Equities analysts forecast that Blueprint Medicines Co. will post -3.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Quarry LP bought a new stake in Blueprint Medicines during the third quarter valued at about $32,000. R Squared Ltd purchased a new stake in shares of Blueprint Medicines during the fourth quarter valued at about $51,000. Covestor Ltd boosted its holdings in shares of Blueprint Medicines by 206.7% in the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 403 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Blueprint Medicines in the 3rd quarter worth approximately $108,000. Finally, Values First Advisors Inc. bought a new position in shares of Blueprint Medicines during the 3rd quarter worth approximately $122,000.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on BPMC shares. Wedbush restated an “outperform” rating and set a $124.00 price objective (down from $135.00) on shares of Blueprint Medicines in a research report on Monday, January 13th. JPMorgan Chase & Co. started coverage on Blueprint Medicines in a research report on Thursday, November 14th. They issued an “overweight” rating and a $126.00 price target for the company. UBS Group started coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They set a “neutral” rating and a $88.00 price objective for the company. StockNews.com raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a research note on Monday, January 13th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $122.72.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.